U
PBYI icon

UBS’s Puma Biotechnology PBYI Stock Holding History

UBS’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$191K Buy
+800
New +$164K ﹤0.01% 5226
2014
Q2 		– Sell
-5,000
Closed -$521K – 10705
2014
Q1 		$521K Buy
+5,000
New +$588K ﹤0.01% 4183

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

UBS's PBYI Position: Q3 2014 in Review

UBS increased its Puma Biotechnology (PBYI) stake by 12% in Q3 2014, buying an estimated $629K and bringing the position to 27,877 shares worth $6.65M. The position accounts for ﹤0.01% of the portfolio, ranked #1768.

UBS first reported a position in PBYI in Q2 2013 and has held it in 6 quarters since. 183 funds tracked by Wall St. Rank hold PBYI as of Q3 2014.

  • UBS held 27,877 shares of Puma Biotechnology worth $6.65M as of Q3 2014.
  • UBS bought 3,062 Puma Biotechnology shares in Q3 2014, an estimated $629K.
  • Puma Biotechnology made up ﹤0.01% of UBS's portfolio in Q3 2014, its #1768 holding.
  • UBS first reported a position in Puma Biotechnology in Q2 2013 and has held it in 6 quarters since.
  • 183 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.